| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0d589b45f5c5957802d4d8b47e8c0d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_843710711bffbc13d22dc1dfa6b41ea8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d241434dd2e686fcc5aab7061164f8c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-164 |
| filingDate |
2008-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1d9498e7dd95079384a62192825e39c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_866a720f8d10ee2961db0a691a13604c |
| publicationDate |
2008-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008100912-A1 |
| titleOfInvention |
Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| abstract |
The present invention is directed to a method of inhibiting allergen-induced airway CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Methods of the invention are useful for treatment and prevention of air-way hyperactivity caused by an allergen, and results in the attenuation of CD1d-restricted immune responses, including treatment of hay fever and asthma are due to air-way hyperactivity, and for systemic administration to attenuate ongoing immune responses. Preferably, these compositions are in a form intended for administration via nasal passages or directly inhaled to the air-ways. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2766042-A4 |
| priorityDate |
2007-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |